Dimerix Valuation Multiples

Dimerix Overview

About Dimerix

Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.

Founded

1975

HQ

Employees

14

Website

dimerix.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $11M

EBITDA: ($10M)

EV

$142M

Valuation Multiples

Multiples.vc

Start free trial

Dimerix Financials

Dimerix reported last 12-month revenue of $11M and negative EBITDA of ($10M).

In the same LTM period, Dimerix generated $11M in gross profit, ($10M) in EBITDA losses, and had net loss of ($7M).

Dimerix P&L

In the most recent fiscal year, Dimerix reported revenue of $4M and EBITDA of ($20M).

Dimerix expects next 12-month revenue of XXX and NTM EBITDA of XXX

Dimerix Stock Performance

Dimerix has current market cap of $170M, and enterprise value of $142M.

Dimerix's stock price is $0.28.

Dimerix Valuation Multiples

Dimerix trades at 12.5x EV/Revenue multiple, and (14.7x) EV/EBITDA.

Dimerix Financial Valuation Multiples

As of April 19, 2026, Dimerix has market cap of $170M and EV of $142M.

Equity research analysts estimate Dimerix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Dimerix has a P/E ratio of (22.7x).

Dimerix Margins & Growth Rates

Dimerix's revenue in the last 12 month grew by 273%.

Dimerix's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.9M for the same period.

Dimerix's rule of 40 is 319% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Dimerix's rule of X is 716% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Dimerix Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Dimerix M&A Activity

Dimerix acquired XXX companies to date.

Last acquisition by Dimerix was on XXXXXXXX, XXXXX. Dimerix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Dimerix Investment Activity

Dimerix invested in XXX companies to date.

Dimerix made its latest investment on XXXXXXXX, XXXXX. Dimerix invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).